Beam Therapeutics Inc. Total Contract Liability
Beam Therapeutics Inc. (BEAM) had Total Contract Liability of $6.66 million as of 2025-12-31, per its 10-K filed 2026-02-24.
Financial Statements › Balance Sheet › Liabilities
us-gaap:ContractWithCustomerLiability · last filed 2026-02-24
- 2025-12-31: Contract with Customer, Liability $6.66M.
- 2024-12-31: Contract with Customer, Liability $142.08M.
- 2023-12-31: Contract with Customer, Liability $178.59M.
- 2022-12-31: Contract with Customer, Liability $338.15M.
| Period end | Contract with Customer, Liability |
|---|---|
| 2025-12-31 | $6.66M 10-K · filed 2026-02-24 |
| 2024-12-31 | $142.08M 10-K · filed 2026-02-24 |
| 2023-12-31 | $178.59M 10-K · filed 2026-02-24 |
| 2022-12-31 | $338.15M 10-K · filed 2025-02-25 |
| 2021-12-31 | $348.57M 10-K · filed 2024-02-27 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Greenland Mines Ltd (GRML) | United States | $2.362B | |
| BIOCRYST PHARMACEUTICALS INC (BCRX) | United States | $2.175B | -6.63 |
| ADMA BIOLOGICS, INC. (ADMA) | United States | $2.131B | 11.16 |
| Kodiak Sciences Inc. (KOD) | United States | $2.090B | -10.12 |
| RECURSION PHARMACEUTICALS, INC. (RXRX) | United States | $2.080B | -3.78 |
| Vericel Corp (VCEL) | United States | $2.011B | 93.97 |
| Denali Therapeutics Inc. (DNLI) | United States | $3.274B | -8.04 |
| Vir Biotechnology, Inc. (VIR) | United States | $1.814B | -6.85 |
| Tarsus Pharmaceuticals, Inc. (TARS) | United States | $3.329B | -58.60 |
| NOVAVAX INC (NVAX) | United States | $1.748B | -6.26 |